menu

Tackling Adverse Events Associated with Disruption of B-Cell Receptor Signaling: A Multispecialty Approach

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Tackling Adverse Events Associated with Disruption of B-Cell Receptor Signaling: A Multispecialty Approach

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
  • Overview

    Preventing or mitigating adverse events (AEs) when utilizing small molecule inhibitors of BTK and Bcl-2 in the management of CLL is critical to improving patient outcomes. Coupling each agent’s unique side-effect profile with the appropriate patient makes the decisions even more complex. Join Drs. Ian Flinn and William Wierda as they deep dive into these issues and offer actionable guidance backed by key clinical trials.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Ian Flinn, MD, PhD
    Director, Lymphoma Research
    Sarah Cannon Research Institute
    Nashville, TN

    Consulting Fees: AbbVie, AstraZeneca, BeiGene, Century Therapeutics, Cogent Biosciences (formerly Unum Therapeutics), Genentech, Genmab, Gilead Sciences, Inc., Great Point Partners, Hutchison MediPharma Ltd., lksuda Therapeutics, lnnoCare Pharma Ltd., Janssen, Juno Pharmaceutical, Kite Pharma, MorphoSys, Novartis, Nurix, Pharmacyclics, Roche, Seagen, Inc. (formerly Seattle Genetics), Servier Pharmaceuticals, Takeda, TG Therapeutics, Verastem Oncology, Vincerx Pharma, Yingli Pharmaceuticals
    Contracted Research: AbbVie, Acerta Pharma, Agios Pharmaceuticals, ArQule, AstraZeneca, BeiGene, Biopath, Bristol Myers Squibb, CALIBR, CALGB, Celgene, City of Hope National Medical Center, Cogent Biosciences (formerly Unum Therapeutics), Constellation Pharmaceuticals, Curis, Inc., CTI BioPharma, Fate Therapeutics, Forma Therapeutics, Forty Seven, Inc., Genentech, Gilead Sciences, Inc., lnnoCare Pharma Ltd., IGM Biosciences, lncyte, Infinity Pharmaceuticals, Janssen, Kite Pharma, Loxo Oncology, Merck & Co., Inc., Millennium Pharmaceuticals, MorphoSys, Myeloid Therapeutics, Novartis, Nurix, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seagen, Inc. (formerly Seattle Genetics), Tessa Therapeutics, TCR2 Therapeutics, TG Therapeutics, Trillium Therapeutics, TRIPHASE Research & Development Corp., Verastem Oncology

    William Wierda, MD, PhD
    D.B. Lane Cancer Research Distinguished Professor
    University of Texas MD Anderson Cancer Center
    Houston, TX

    Contracted Research: AbbVie, AstraZeneca/Acerta Pharma, Bristol Myers Squibb (Juno & Celgene), Cyclacel Pharmaceuticals, Inc., Genentech, Gilead Sciences, Inc., GlaxoSmithKline/Novartis, Janssen, Kite Pharma, Loxo Oncology/Eli Lilly and Company, Oncternal Therapeutics, Inc., Pharmacyclics, Viracta Therapeutics (formerly Sunesis), Viridian Therapeutics (formerly miRagen Therapeutics), Xencor

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel, PhD, has nothing to disclose.
    • Brian McDonough, MD has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Terra Sumstine has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Recognize adverse events associated with BTK and BCL-2 inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
    2. Develop strategies to manage toxicities associated with disruption of B-cell receptor signaling in patients undergoing treatment for CLL or SLL
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists, hematologist oncologists, medical oncologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 contact nursing hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until June 30, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from AbbVie and Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
  • Overview

    Preventing or mitigating adverse events (AEs) when utilizing small molecule inhibitors of BTK and Bcl-2 in the management of CLL is critical to improving patient outcomes. Coupling each agent’s unique side-effect profile with the appropriate patient makes the decisions even more complex. Join Drs. Ian Flinn and William Wierda as they deep dive into these issues and offer actionable guidance backed by key clinical trials.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Ian Flinn, MD, PhD
    Director, Lymphoma Research
    Sarah Cannon Research Institute
    Nashville, TN

    Consulting Fees: AbbVie, AstraZeneca, BeiGene, Century Therapeutics, Cogent Biosciences (formerly Unum Therapeutics), Genentech, Genmab, Gilead Sciences, Inc., Great Point Partners, Hutchison MediPharma Ltd., lksuda Therapeutics, lnnoCare Pharma Ltd., Janssen, Juno Pharmaceutical, Kite Pharma, MorphoSys, Novartis, Nurix, Pharmacyclics, Roche, Seagen, Inc. (formerly Seattle Genetics), Servier Pharmaceuticals, Takeda, TG Therapeutics, Verastem Oncology, Vincerx Pharma, Yingli Pharmaceuticals
    Contracted Research: AbbVie, Acerta Pharma, Agios Pharmaceuticals, ArQule, AstraZeneca, BeiGene, Biopath, Bristol Myers Squibb, CALIBR, CALGB, Celgene, City of Hope National Medical Center, Cogent Biosciences (formerly Unum Therapeutics), Constellation Pharmaceuticals, Curis, Inc., CTI BioPharma, Fate Therapeutics, Forma Therapeutics, Forty Seven, Inc., Genentech, Gilead Sciences, Inc., lnnoCare Pharma Ltd., IGM Biosciences, lncyte, Infinity Pharmaceuticals, Janssen, Kite Pharma, Loxo Oncology, Merck & Co., Inc., Millennium Pharmaceuticals, MorphoSys, Myeloid Therapeutics, Novartis, Nurix, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seagen, Inc. (formerly Seattle Genetics), Tessa Therapeutics, TCR2 Therapeutics, TG Therapeutics, Trillium Therapeutics, TRIPHASE Research & Development Corp., Verastem Oncology

    William Wierda, MD, PhD
    D.B. Lane Cancer Research Distinguished Professor
    University of Texas MD Anderson Cancer Center
    Houston, TX

    Contracted Research: AbbVie, AstraZeneca/Acerta Pharma, Bristol Myers Squibb (Juno & Celgene), Cyclacel Pharmaceuticals, Inc., Genentech, Gilead Sciences, Inc., GlaxoSmithKline/Novartis, Janssen, Kite Pharma, Loxo Oncology/Eli Lilly and Company, Oncternal Therapeutics, Inc., Pharmacyclics, Viracta Therapeutics (formerly Sunesis), Viridian Therapeutics (formerly miRagen Therapeutics), Xencor

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel, PhD, has nothing to disclose.
    • Brian McDonough, MD has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Terra Sumstine has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Recognize adverse events associated with BTK and BCL-2 inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
    2. Develop strategies to manage toxicities associated with disruption of B-cell receptor signaling in patients undergoing treatment for CLL or SLL
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists, hematologist oncologists, medical oncologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 contact nursing hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until June 30, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from AbbVie and Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule12 Aug 2022
Webpack App